Eyeworld

by Title ASCRS NEWS Heading Name title Contact Name: email 8 | EYEWORLD | FALL 2025 continued from page 3 Indication and Usage Qlosi TM is indicated for the treatment of presbyopia in adults. Important Safety Information Contraindications Hypersensitivity Warnings and Precautions Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination. Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss. Qlosi TM is not recommended to be used when iritis is present. Qlosi TM should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi TM and wait 10 minutes before reinsertion. Avoid touching the tip of the vial to the eye or any other su-ace. Adverse Reactions The most common adverse reactions (5% to 8%) are instillation site pain and headaches. Please see full Prescribing Information here: www.qlosi.com/prescribing-information ©2025 Orasis Pharmaceuticals, Inc. All Rights Reserved. QLO. QLO.00117. • Embrace advanced diagnostic tools: Move beyond standard autorefractors and incorporate topography and wavefront diagnostics to get accurate starting points for routine and complex cases. Use "old school" techniques like retinoscopy when appropriate, as these can provide valuable insights that automated systems miss. • Consider innovative solutions: Explore techniques like pinhole pupilloplasty for patients with irregular astigma- tism who can't be helped by traditional methods. This can reduce the need for corneal transplants and provide immediate visual improvement. • Early intervention philosophy: Intervene earlier with laser treatments, MIGS, or other therapies before glaucomatous diseases progress and tissue damage be- comes irreversible, maximizing the potential for positive outcomes. Other important topics include the impact of emerging antibody drug conjugates (ADCs) on ocular health, the basics of pigment dispersion syndrome and pigmentary glaucoma, and updates from the ASCRS Foundation and ASCRS Government Relations. On the topic of government relations, we are facing another proposed cut to cataract reimbursements. As you know, cataract surgery reimbursements have steadily de- clined in recent years, creating financial pressures for oph- thalmologists and surgical centers. Medicare and private insurers have reduced payments, citing efficiency gains, improved technology, and budget constraints. While surgi- cal volume has increased, revenue per case has dropped, forcing practices to optimize workflow, reduce overhead, and adopt cost-saving measures. In 2026, CMS is propos- ing reducing the Medicare reimbursement for CPT 66984 (routine cataract removal with IOL) from $521.75 in 2025 to $466.87 in 2026, an approximate 11% cut. This marks a substantial reduction, adding to the long-term trend of declining payments for cataract-related procedures. This poses yet another headwind for us as we continue to face decreasing reimbursements. Certainly, embracing premium IOLs and elective surgical upgrades can offset losses, but the continued downward trend of insurance reimburse- ment for cataract surgery is extremely concerning. Your active participation in government relations activity is needed! Please continue to support our ASCRS eyePAC, write letters to your local government officials, participate in advocacy sessions, and consider attending the annual Legislative Fly-In in Washington, D.C. I hope you enjoy reading this issue of EyeWorld. As always, if you have any suggestions for topics, improvements, etc., please feel free to reach out to me at gargs@uci.edu.

• Blank Page
• Blank Page (1)